Screener
CRISPR Therapeutics CRSP Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Deferred revenue | (427) | (824) |
| Operating lease assets and liabilities | (1,521) | (1,151) |
| Other liabilities, net | (199) | (10,541) |
| Net cash used in operating activities | (108,897) | (53,947) |
| Investing activities: | ||
| Purchase of property, plant and equipment | (504) | (206) |
| Investment in equity securities | (4,615) | (5,000) |
| Purchases of marketable securities | (746,089) | (200,730) |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's operating cash flow?
- CRISPR Therapeutics (CRSP) reported operating cash flow of -$108.9M in Q1 2026.
- How has CRISPR Therapeutics's operating cash flow changed year-over-year?
- CRISPR Therapeutics's operating cash flow decreased by 101.9% year-over-year, from -$53.95M to -$108.9M.
- What is the long-term trend for CRISPR Therapeutics's operating cash flow?
- Over 3 years (2022 to 2025), CRISPR Therapeutics's operating cash flow has grown at a -11.4% compound annual growth rate (CAGR), from -$495.74M to -$345.01M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about CRISPR Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude